within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB11_Pixantrone;

model Pixantrone
  extends Pharmacolibrary.Drugs.ATC.L.L01DB11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01DB11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pixantrone is an antineoplastic agent belonging to the class of aza-anthracenediones. It is structurally related to mitoxantrone and is used primarily for the treatment of relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixantrone has been granted conditional marketing authorization in the European Union but is not FDA-approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (mostly with non-Hodgkin lymphoma) receiving pixantrone as monotherapy, intravenous administration.</p><h4>References</h4><ol><li><p>She, Z, et al., &amp; Deng, Y (2014). The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate. <i>Biomaterials</i> 35(19) 5216–5225. DOI:<a href=\"https://doi.org/10.1016/j.biomaterials.2014.03.022\">10.1016/j.biomaterials.2014.03.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24703714/\">https://pubmed.ncbi.nlm.nih.gov/24703714</a></p></li><li><p>Kurmasheva, RT, et al., &amp; Smith, MA (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. <i>Pediatric blood &amp; cancer</i> 61(5) 922–924. DOI:<a href=\"https://doi.org/10.1002/pbc.24800\">10.1002/pbc.24800</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24166988/\">https://pubmed.ncbi.nlm.nih.gov/24166988</a></p></li><li><p>Dawson, LK, et al., &amp; Smyth, JF (2000). A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. <i>European journal of cancer (Oxford, England : 1990)</i> 36(18) 2353–2359. DOI:<a href=\"https://doi.org/10.1016/s0959-8049(00)00342-7\">10.1016/s0959-8049(00)00342-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11094309/\">https://pubmed.ncbi.nlm.nih.gov/11094309</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Pixantrone;
